DIAGNOSTIC SIGNIFICANCE OF BIOMARKERS (CA-125, HE4) IN OVARIAN CANCER SCREENING

Authors

  • Khurramova Zahro Uktam kizi Student of group 225-A, 2nd Faculty of General Medicine, Tashkent State Medical Academy.
  • Zulfikariyev Diyorbek Davronbekovich Senior Lecturer, Department of Medical Radiology No

DOI:

https://doi.org/10.55640/

Keywords:

ovarian cancer, CA-125, HE4, ROMA index, biomarker, screening. Introduction (Fragment):

Abstract

This article analyzes the diagnostic significance of CA-125 and HE4 biomarkers in the early detection of ovarian cancer (OC). Research indicates that while CA-125 is a classic marker, its sensitivity in the early stages and specificity regarding benign tumors are relatively low. In contrast, the HE4 biomarker is distinguished by the fact that its levels do not rise in gynecological conditions such as endometriosis. The ROMA index, which integrates these two markers with the patient’s menopausal status, provides the highest accuracy (sensitivity ~90%) in diagnosing ovarian cancer.

Downloads

Download data is not yet available.

References

1.Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians. 2021;71(3):209-249.

2.Karlan BY. Ovarian Cancer Screening: Progress and Path forward. Gynecologic Oncology. 2022;166(1):1-3.

3.Crosbie EJ, Kitson S, McAlpine JN. Ovarian Cancer. The Lancet. 2022;399(10337):1829-1840.

4.Moore RG, Miller MC, Disilvestro P, et al. Evaluation of the ROMA Algorithm for Aiding in the Diagnostic Workup of Women with a Pelvic Mass. Gynecologic Oncology. 2021;161(1):153-159.

5.Dochez V, Caillon H, Vaucel E, et al. Biomarkers and Algorithms for Diagnosis of Ovarian Cancer: CA125, HE4, ROMA and Risk of Malignancy Index (RMI). Review of the Literature. 2019;12(1):28-35.

6.Ueland FR. A Perspective on Ovarian Cancer Biomarkers: Past, Present and Future. Obstetrics & Gynecology. 2021;137(1):153-161.

7.Li F, Tie R, Chang K, et al. Comparison of HE4, CA125 and ROMA Index in the Diagnosis of Ovarian Cancer: A Meta-analysis. Clinica Chimica Acta. 2020;501:135-144.

8.Gorp TV, Veldman J, Van Calster B, et al. Subjective Assessment by Ultrasound is Superior to the ROMA Score and the Risk of Malignancy Index (RMI) for the Identification of Ovarian Cancer. Ultrasound in Obstetrics & Gynecology. 2021;57(5):824-831.

9.Gentry-Maharaj A, Burnell M, Ryan A, et al. HE4 as a Second-line Test to Improve the Specificity of CA125 in Ovarian Cancer Screening. Cancer Epidemiology, Biomarkers & Prevention. 2020;29(11):2188-2193.

10.Yang Z, Zhao B, Luan Z, et al. The Diagnostic Value of HE4, CA125 and ROMA Index in Ovarian Cancer: A Systematic Review and Meta-analysis. Frontiers in Oncology. 2021;11:670054.

11.Matas AJ, Sanchez-Gomez J. Performance of ROMA Index in Premenopausal and Postmenopausal Women: A Systematic Review. Journal of Clinical Medicine. 2023;12(4):1452.

12.Berek JS, Kehoe ST, Kumar L, Friedlander M. Cancer of the Ovary, Fallopian Tube, and Peritoneum. International Journal of Gynecology & Obstetrics. 2018;143:59-77.

13.Yilmaz A, Uzun O. Differential Diagnosis of Endometrioma and Ovarian Cancer: The Role of HE4. European Journal of Obstetrics & Gynecology. 2022;270:45-51.

14.Anastasi E, Gigli S, Cassone R, et al. The Strategic Role of HE4 in the Management of Ovarian Cancer. Expert Review of Molecular Diagnostics. 2020;20(11):1111-1117.

15.Kim B, Park Y, Kim B, et al. Diagnostic Performance of CA125, HE4, and ROMA Index in Ovarian Cancer. Annals of Laboratory Medicine. 2019;39(5):438-445.

16.Chornokur G, Amankwah EK, Pirie A, et al. Ovarian Cancer: Challenges and Progress. Journal of Cancer Epidemiology. 2023;2023:5421098.

17.Shen Y, Liang Y, Lou H, et al. Comparison of Diagnostic Performance of CA125 and HE4 in Patients with Different Types of Ovarian Tumors. Scientific Reports. 2022;12(1):14512.

18.Goff BA. Ovarian Cancer: Screening and Early Detection. UpToDate. 2024; (Updated review).

19.Scalici J, Wheeler L. The Utility of HE4 and CA125 in the Diagnosis of Ovarian Cancer. Oncology (Williston Park). 2021;35(10):650-658.

Downloads

Published

2026-05-05

Issue

Vol. 5 No. 5 (2026): Journal of Multidisciplinary Sciences and Innovations

Section

Articles

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors retain the copyright of their manuscripts, and all Open Access articles are disseminated under the terms of the Creative Commons Attribution License 4.0 (CC-BY), which licenses unrestricted use, distribution, and reproduction in any medium, provided that the original work is appropriately cited. The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.

How to Cite

DIAGNOSTIC SIGNIFICANCE OF BIOMARKERS (CA-125, HE4) IN OVARIAN CANCER SCREENING. (2026). Journal of Multidisciplinary Sciences and Innovations, 5(5), 303-307. https://doi.org/10.55640/

Similar Articles

11-20 of 2804

You may also start an advanced similarity search for this article.